« Back to Record
Citation APA

Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J. C., Graas, M.-P., Kennedy, M. J., Ciruelos Gil, E. M., Schneeweiss, A., Zubel, A., Groos, J., Melezínková, H., & Awada, A. (2013). Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of clinical oncology, 31(20), 2586-2592. doi:10.1200/JCO.2012.46.2408


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/199116

Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J. C., Graas, M.-P., Kennedy, M. J., Ciruelos Gil, E. M., Schneeweiss, A., Zubel, A., Groos, J., Melezínková, H., & Awada, A. (2013). Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of clinical oncology, 31(20), 2586-2592. doi:10.1200/JCO.2012.46.2408